Bayer to sell men’s health product Nebido™ to Grünenthal
Supports ongoing transformation of Bayer’s Pharma business to focus on key areas of future medical innovation / Transaction value of up to 500 million Euro / Closing expected by end of 2022
Berlin, July 14, 2022 – Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer’s men’s health product Nebido™ (testosterone undecanoate), for a purchase price totaling up to 500 million Euro.